FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032133020> ?p ?o ?g. }

• W3032133020 endingPage "184" @default.
• W3032133020 startingPage "180" @default.
• W3032133020 abstract "ObjectiveTo investigate the optimal dosage of thoracic radiotherapy in patients diagnosed with extensive stage small cell lung cancer (ES-SCLC).MethodsClinical data of ES-SCLC patients admitted to Tianjian Medical University Cancer Institute& Hospital between February 2010 and October 2015 were retrospectively analyzed. All patients received the first-line induction chemotherapy. Subsequently, 216 patients without progression after the first-line induction chemotherapy were apportioned to the thoracic radiotherapy (n=180) group and chemotherapy alone group (n=36). According to the distribution characteristics of the biological equivalent dose, all patients were assigned into the A (31.3-40.2 Gy, n=23), B (46.0-46.8 Gy, n=38), C (49.5-53.7 Gy, n=43) and D groups (55.1-60.6 Gy, n=76). For the subgroup analysis, the low (31.3-46.8 Gy, n=61) and high dose groups (49.5-60.6 Gy, n=119) were divided. Kaplan-Meier survival analysis was used for prognostic analysis. Cox’s regression model was conducted for multivariate prognostic analysis. Propensity score matching was utilized to control the confounding variables.ResultsThe median overall survival of all patients was 13.2 months, and 8.3, 11.0, 15.8, 17.8 and 8.1 months for patients in the A, B, C, D and chemotherapy alone groups, respectively (all P=0.000). The median overall survival did not significantly differ between A and B/chemotherapy groups (P=0.172, P=0.495), and similar results were obtained between the C and D groups (P=0.624). The median overall survival in the B group was significantly longer than that in the chemotherapy alone group (P=0.020). Statistical significance was noted between C and D groups, and A and B groups (all P<0.05). The median progression-free survival for all patients was 8.7 months, and 6.5, 7.6, 11.8, 12.4 and 6.1 months in the A, B, C, D and chemotherapy alone groups, respectively (all P=0.000). The median progression-free survival did not significantly differ between A and B chemotherapy groups (P=0.588, P=0.668). The progression-free survival in the B group was slightly longer than that in the chemotherapy group without statistical significance (P=0.070). No statistical significance was observed between the C and D groups (P=0.627). Statistical significance was noted between C and D groups, and A and B groups (all P<0.02). Uni-and multi-variate analyses prompted that the number of metastatic lesions and dose of thoracic radiotherapy were the independent predictors of the overall survival and progression-free survival (both P<0.05). Concurrent chemoradiotherapy was the independent predictor of the overall survival (P=0.018). After the propensity score matching, the median overall survival and progression-free survival significantly differed between the low (n=50) and high dose groups (n=50)(10.9 vs. 17.5 months, P=0.045; 7.4 vs. 10.7 months, P=0.014).ConclusionsA relatively high dose ranging from 49.5 to 53.7 Gy is recommended during thoracic radiotherapy for ES-SCLC patients. An excessively low dose (≤40.2 Gy) probably fails to prolong the survival time, and an extremely high dose (≥55.1 Gy) cannot enable the patients to obtain survival benefits.Key words: Lung neoplasms/radiotherapy; Prognosis" @default.
• W3032133020 created "2020-06-05" @default.
• W3032133020 creator A5014086322 @default.
• W3032133020 creator A5053769864 @default.
• W3032133020 creator A5064729480 @default.
• W3032133020 creator A5080338192 @default.
• W3032133020 creator A5083509837 @default.
• W3032133020 creator A5088549421 @default.
• W3032133020 creator A5091336301 @default.
• W3032133020 date "2019-03-15" @default.
• W3032133020 modified "2023-09-26" @default.
• W3032133020 title "Analysis of optimal dose of thoracic radiotherapy for patients with extensive stage small cell lung cancer" @default.
• W3032133020 doi "https://doi.org/10.3760/cma.j.issn.1004-4221.2019.03.004" @default.
• W3032133020 hasPublicationYear "2019" @default.
• W3032133020 type Work @default.
• W3032133020 sameAs 3032133020 @default.
• W3032133020 citedByCount "0" @default.
• W3032133020 crossrefType "journal-article" @default.
• W3032133020 hasAuthorship W3032133020A5014086322 @default.
• W3032133020 hasAuthorship W3032133020A5053769864 @default.
• W3032133020 hasAuthorship W3032133020A5064729480 @default.
• W3032133020 hasAuthorship W3032133020A5080338192 @default.
• W3032133020 hasAuthorship W3032133020A5083509837 @default.
• W3032133020 hasAuthorship W3032133020A5088549421 @default.
• W3032133020 hasAuthorship W3032133020A5091336301 @default.
• W3032133020 hasConcept C10515644 @default.
• W3032133020 hasConcept C121608353 @default.
• W3032133020 hasConcept C126322002 @default.
• W3032133020 hasConcept C143998085 @default.
• W3032133020 hasConcept C146357865 @default.
• W3032133020 hasConcept C151730666 @default.
• W3032133020 hasConcept C17923572 @default.
• W3032133020 hasConcept C187960798 @default.
• W3032133020 hasConcept C2776256026 @default.
• W3032133020 hasConcept C2776694085 @default.
• W3032133020 hasConcept C2989005 @default.
• W3032133020 hasConcept C38180746 @default.
• W3032133020 hasConcept C44249647 @default.
• W3032133020 hasConcept C50382708 @default.
• W3032133020 hasConcept C509974204 @default.
• W3032133020 hasConcept C71924100 @default.
• W3032133020 hasConcept C86803240 @default.
• W3032133020 hasConcept C90924648 @default.
• W3032133020 hasConceptScore W3032133020C10515644 @default.
• W3032133020 hasConceptScore W3032133020C121608353 @default.
• W3032133020 hasConceptScore W3032133020C126322002 @default.
• W3032133020 hasConceptScore W3032133020C143998085 @default.
• W3032133020 hasConceptScore W3032133020C146357865 @default.
• W3032133020 hasConceptScore W3032133020C151730666 @default.
• W3032133020 hasConceptScore W3032133020C17923572 @default.
• W3032133020 hasConceptScore W3032133020C187960798 @default.
• W3032133020 hasConceptScore W3032133020C2776256026 @default.
• W3032133020 hasConceptScore W3032133020C2776694085 @default.
• W3032133020 hasConceptScore W3032133020C2989005 @default.
• W3032133020 hasConceptScore W3032133020C38180746 @default.
• W3032133020 hasConceptScore W3032133020C44249647 @default.
• W3032133020 hasConceptScore W3032133020C50382708 @default.
• W3032133020 hasConceptScore W3032133020C509974204 @default.
• W3032133020 hasConceptScore W3032133020C71924100 @default.
• W3032133020 hasConceptScore W3032133020C86803240 @default.
• W3032133020 hasConceptScore W3032133020C90924648 @default.
• W3032133020 hasIssue "3" @default.
• W3032133020 hasLocation W30321330201 @default.
• W3032133020 hasOpenAccess W3032133020 @default.
• W3032133020 hasPrimaryLocation W30321330201 @default.
• W3032133020 hasRelatedWork W2000708012 @default.
• W3032133020 hasRelatedWork W2028728932 @default.
• W3032133020 hasRelatedWork W2090724151 @default.
• W3032133020 hasRelatedWork W2113416899 @default.
• W3032133020 hasRelatedWork W2159103156 @default.
• W3032133020 hasRelatedWork W2172270945 @default.
• W3032133020 hasRelatedWork W2185093821 @default.
• W3032133020 hasRelatedWork W2265294803 @default.
• W3032133020 hasRelatedWork W2365185494 @default.
• W3032133020 hasRelatedWork W2394459289 @default.
• W3032133020 hasRelatedWork W2548496660 @default.
• W3032133020 hasRelatedWork W2885208349 @default.
• W3032133020 hasRelatedWork W2886622072 @default.
• W3032133020 hasRelatedWork W2942272799 @default.
• W3032133020 hasRelatedWork W3029292771 @default.
• W3032133020 hasRelatedWork W3030310373 @default.
• W3032133020 hasRelatedWork W3031650156 @default.
• W3032133020 hasRelatedWork W3031823823 @default.
• W3032133020 hasRelatedWork W2187589592 @default.
• W3032133020 hasRelatedWork W3029157910 @default.
• W3032133020 hasVolume "28" @default.
• W3032133020 isParatext "false" @default.
• W3032133020 isRetracted "false" @default.
• W3032133020 magId "3032133020" @default.
• W3032133020 workType "article" @default.